---
schema_version: "secwatch.filing_event.v1"
accession: "0000784199-22-000034"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2022-02-17T23:59:59+00:00"
generated_at: "2026-06-27T07:13:06.589645+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Artivion Q4 revenue record $79.4M (+16.9%), net loss widens to $20.1M; guides 2022 rev $319-325M

## Summary
- Q4 revenue $79.4M, up 16.9% GAAP; net loss ($20.1M) vs ($3.5M) in prior year.
- Non-GAAP Q4 net loss ($141K) vs income $7.9M; full year non-GAAP net income $4.9M.
- Full year revenue $298.8M (+18%); net loss ($14.8M) narrowed from ($16.7M) in 2020.
- 2022 outlook: constant currency revenue growth 9-11%; GAAP revenue $319-325M with $6M FX headwind.
- FDA approved AMDS trial start; PMA filed for PerClot US approval; PROACT trials progressing.

## SEC filing metadata
- accession: 0000784199-22-000034
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2022-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000078419922000034/0000784199-22-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000078419922000034/aort-20220217x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000784199-22-000034
- JSON: https://secwatch.observer/filing/0000784199-22-000034.json
- Plain text: https://secwatch.observer/filing/0000784199-22-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.